The Department of Pharmaceuticals on November 10, 2026 announced the extension of the Production Linked Incentive Scheme for Promoting Domestic Manufacturing of Medical Devices (PLI-MD) up to FY 2035–36, with an approximate outlay of ₹2,700 crore. Fresh applications have been invited under the scheme, with the online application portal expected to become operational within 10 days of the announcement dated November 10, 2026.
The revised scheme provides applicants with three years to establish manufacturing facilities across four target segments: (i) medical consumables, disposables and implants; (ii) critical components; (iii) high-end medical devices at a nascent stage of domestic manufacturing; and (iv) high-end medical devices currently assembled in India. The tapering incentive rates will average approximately 5% for TS1, 9% for TS2 and TS3, and 6% for TS4. The minimum sales threshold for claiming incentives has been discontinued, the minimum investment requirement has been reduced, and applicants may submit multiple applications across one or more target segments.
The revised guidelines aim to simplify eligibility and incentive-claim procedures, promote critical component manufacturing, strengthen domestic supply chains and encourage value-chain integration. The scheme focuses on increasing domestic manufacturing of high-end medical devices and reducing import dependence while improving the competitiveness of Indian manufacturers.
[Release ID: 2334770]
